Gene: LYPD1
Official Full Name: LY6/PLAUR domain containing 1provided by HGNC
Gene Summary: Predicted to enable acetylcholine receptor inhibitor activity. Predicted to be involved in acetylcholine receptor signaling pathway. Predicted to act upstream of or within several processes, including behavioral fear response; cholinergic synaptic transmission; and negative regulation of protein localization to plasma membrane. Predicted to be located in extracellular region and plasma membrane. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO30523 | LYPD1 Knockout cell line (HeLa) | Human | LYPD1 | 1:3~1:6 | Negative | Online Inquiry |
KO30524 | LYPD1 Knockout cell line (HEK293) | Human | LYPD1 | 1:3~1:6 | Negative | Online Inquiry |
KO30525 | LYPD1 Knockout cell line (A549) | Human | LYPD1 | 1:3~1:4 | Negative | Online Inquiry |
LYPD1 Gene Knockout Cell Lines represent a groundbreaking tool in the field of molecular biology, specifically designed to facilitate the study of the LYPD1 gene, an integral factor in various biological processes, including immune responses and cell signaling. By utilizing CRISPR-Cas9 technology, these cell lines allow for precise and efficient gene disruption, providing researchers with a reliable platform to elucidate the functional role of LYPD1 in physiological and pathological contexts.
These knockout cell lines function by disrupting the normal coding sequence of the LYPD1 gene, thus enabling the investigation of downstream effects and the analysis of phenotypic changes in cellular mechanisms. The absence of LYPD1 can alter cellular responsiveness to stimuli, affecting pathways such as T cell activation and tumor progression, making these lines particularly relevant in cancer research and immunology.
The scientific importance of LYPD1 Gene Knockout Cell Lines lies in their capacity to advance our understanding of complex biological systems and disease mechanisms. They are invaluable in preclinical studies, genetic screening, and therapeutic target validation. Their application ranges from studying autoimmune diseases to developing novel cancer therapies, enhancing both research and potential clinical outcomes.
Compared to conventional gene-knockout methods, our LYPD1 Gene Knockout Cell Lines offer a higher gene-editing specificity and efficiency, which minimizes off-target effects. Furthermore, these cell lines come fully characterized, saving researchers vital time and resources, and allowing for immediate experimental application.
For researchers and clinicians exploring the intricacies of immune regulation or tumor biology, the LYPD1 Gene Knockout Cell Lines not only provide a refined method to investigate the gene's functional roles but also allow for the exploration of targeted therapeutic strategies. With our commitment to precision and innovation, our company stands at the forefront of producing high-quality biological products that empower the scientific community in their quest for knowledge and therapeutic advancements.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.